Gizachew Yilak ^1* Befkad Derese ¹ Amsalu Baylie ¹ Bogale Molla ¹ Addisu Getie ² Dejen Tsegaye ² Mulat Ayele ¹ Eyob Shitie ¹

• ¹ Woldia University, Woldiya, Ethiopia
• ² Debre Markos University, Debre Marqos, Ethiopia

Introduction: Gestational Trophoblastic Disease is comprised of different placenta-related conditions with potential health risks. Studies conducted in East Africa have reported varying magnitude levels, and no comprehensive review has been conducted to determine the overall magnitude of Gestational Trophoblastic Disease in this region. This review aims to estimate the magnitude and identify predictors of Gestational Trophoblastic Disease in East Africa.In adherence to PRISMA standards, we conducted a systematic review and metaanalysis of articles obtained from PubMed, Cochrane Library, and Google Scholar. These articles have focused on investigating the magnitude and determinants of Gestational Trophoblastic Disease. Heterogeneity across studies was assessed using Q and I2 tests. We employed a weighted inverse variance random effects model to assess the magnitude and effect size of linked covariates. Publication bias was evaluated using funnel plots and Egger regression tests. In addition, a sensitivity analysis was conducted to evaluate the impact of the included studies.Results: Eleven studies were included in this analysis. The pooled magnitude of Gestational Trophoblastic Disease was 10.54% (95% CI: 8.84 -12.25; I2 = 100%; p < 0.001). The presence of a previous history of Gestational Trophoblastic Disease was associated with gestational trophoblastic disease, with an adjusted odds ratio (AOR) of 3.17 (95% CI: 0.64 -5.69; I2 = 75.2%; p = 0.018). Grand multiparty (having multiple pregnancies) was associated with Gestational Trophoblastic Disease an AOR of 8.9 (95% CI: 2.75 -15.06; I2 = 76%; p = 0.041).The magnitudes of complete and partial molar pregnancies were 37.84% (95% CI: 5.85 -69.83; I2 = 100%; p = 0.001) and 11.78% (95% CI: 9.67 -13.90; I2 = 100%; p = 0.00), respectively.This study found that Gestational Trophoblastic Disease remains a high burden at research facilities. Mothers with a history of Gestational Trophoblastic Disease and those with multiple pregnancies are at an increased risk. Additionally, a significant number of patients in East Africa tend to seek medical attention for Gestational Trophoblastic Disease at a later stage, indicating delays in accessing health care. Early detection and improved access to healthcare are crucial for managing gestational trophoblastic diseases in this region.